TheraSense

Share

TheraSense

 •  January 19

ENHANCED SYSTEM ALLOWS BETTER THREE-DIMENSIONAL IMAGES OF ARRHYTHMIAS IN THE HEART
Abbott (NYSE: ABT) announced today the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™ to map cardiac arrhythmias during ablation treatments. The first commercial...

TheraSense

 •  January 4

Abbott (NYSE: ABT) announced today it has completed the acquisition of St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. The transaction provides Abbott with expanded opportunities for future growth and is an important part of the company's ongoing effort to develop a strong, diverse portfolio of devices,...

TheraSense

 •  December 8, 2016

- FOUR ADVOCATE HEALTH CARE HOSPITALS FOLLOWED MORE THAN 1,200 ADULTS AT-RISK OF MALNUTRITION DURING THEIR STAY[1]
- STUDY CONFIRMS THE NEED FOR HOSPITALS TO USE A VALIDATED NUTRITION SCREENING TOOL AT ADMISSION, INITIATE EARLY TREATMENT FOR PATIENTS AT-RISK OF MALNUTRITION AND PROVIDE NUTRITION EDUCATION AT DISCHARGE
While proper nutrition is...

TheraSense

 •  October 18, 2016

- The agreement is an important step toward completion of Abbott's acquisition of St. Jude Medical
- Abbott's acquisition of St. Jude Medical is expected to close by year-end
Abbott (NYSE: ABT) and St. Jude Medical, Inc. (NYSE: STJ) announced today an agreement in principle to sell certain products to Terumo Corporation. The transaction reflects a...

TheraSense

 •  September 28, 2016

- FREESTYLE LIBRE PRO IS A CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM DESIGNED TO PROVIDE A CLEAR, VISUAL SNAPSHOT OF A PATIENT'S GLUCOSE LEVELS, TRENDS AND PATTERNS FOR UP TO 14 DAYS
- REQUIRES NO FINGERSTICKS TO CALIBRATE THE SYSTEM -- AN ADVANTAGE OVER OTHER PROFESSIONAL USE CGM DEVICES
- SIGNIFICANTLY LOWER COST THAN OTHER PROFESSIONAL CGM...